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Clinically, human glioblastoma (GBM) may develop de novo or from a low-grade glioma (secondary GBM), and molecular alterations
in the two pathways may differ. This study examined the status of Survivin expression and apoptosis in 30 primary and 26 secondary
GBMs. Our results show that cytoplasmic Survivin positivity was significantly (Po0.001) more frequent in primary GBMs (83%) than
that in secondary GBMs (46%). In addition, an inverse correlation of cytoplasmc Survivin positivity with GBM apoptotic index, and a
positive association between cytoplasmic Survivin and size of the tumours were observed. These results suggest that cytoplasmic
Survivin, via its antiapoptotic function, may be involved in the tumorigenesis of many primary GBMs, but only in a small fraction of
secondary GBMs. Furthermore, the overall progression times from low-grade precursor lesions to secondary GBMs were significantly
shorter (Po0.05) in cytoplasmic Survivin-positive cases (mean, 15.6 months) than those in Survivin-negative cases (mean, 23.8
moths), and the positive expression level of Survivin in cytoplasm was upregulated in most secondary GBMs when compared to
matched pre-existing low-graded lesions. These results suggest that the increased accumulation of Survivin in the cytoplasm of more
malignant glioma cells may prove to be a selective advantage, thus accelerating progression to a more aggressive phenotype.
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Survivin is located on chromosome 17q25. It was initially
identified as a gene with structural homology to a family of genes
known as inhibitors of apoptosis (IAPs) (Ambrosini et al, 1997).
Survivin is known to be normally expressed at high levels in fetal
tissue but absent in most normal adult differentiated cells (Adida
et al, 1998). It is expressed extensively in common human cancers,
such as colorectal carcinoma (Kawasaki et al, 1998), lung cancer
(Monzo et al, 1999), and oesophageal carcinoma (Kato et al, 2001),
and the increased expression of Survivin appears to be associated
with the aggressive nature and/or poor prognosis of the above
cancers. It is thought that Survivin enhances survival of tumour
cells primarily through its antiapoptotic function via direct
blocking of the terminal effecter cell-death proteases, caspases-3
and -7, which are distinct from the BCL-2 family of antiapoptotic
proteins (Shin et al, 2001). In human gliomas, some reports have
documented that the increased expression of cytoplasmic Survivin,
detected by immunohistochemistry (IHC), in gliomas was
correlated with an ascending pathological grade of tumour (Sasaki
et al, 2002; Jiao et al, 2004). In addition, in glioblastoma multiform
(GBM, WHO, grade IV), patients with detectable Survivin
expression by Western blot analysis have been observed to have
significantly shorter overall survival times compared with those
without detectable expression (Chakravarti et al, 2002). These
results suggest that Survivin might be involved in tumorigenesis
and progression of GBM.
It has been suggested that the development of GBM could be
along two distinct pathogenic pathways (Watanabe et al, 1996).
Primary GBM may arise from de novo after a short clinical history
without an identifiable less-malignant precursor lesion and
frequently contains EGFR amplification/overexpression, PTEN
mutation, homozygous p16 deletion, and loss of heterozygosity
(LOH) on chromosome 19q. Secondary GBM often develops more
slowly from a low-grade or anaplastic astrocytoma. P53 mutations
and LOH on chromosome 10q are often observed, while
amplification/overexpression of EGFR is most often lacking
(Watanabe et al, 1996; Nakamura et al, 2000). This suggests that
primary and secondary GBMs develop differently on a genetic
level. However, whether or not the expression of Survivin is
different between primary and secondary GBMs and the potential
role of Survivin in tumorigenesis of GBMs in different pathogenic
pathways have not been described to date.
In the present study, we evaluated the protein expression of
Survivin by IHC in a total of 56 GBMs, including 30 primary and 26
secondary GBMs, and in 15 matched low-grade precursor lesions
(grade II or III gliomas) of secondary GBMs. Since Survivin has
both nuclear and cytoplasmic targets, which appear to serve
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sdifferent functions (Mahotka et al, 2002), two different commer-
cially available Survivin antibodies, which recognise predominantly
nuclear and cytoplasmic forms of Survivin, were used (Altura et al,
2003). Nuclear Survivin has been suggested to play an important
role in chromosomal segregation during mitosis (Uren et al, 2000;
Honda et al, 2003), while cytoplasmic Survivin has been
characterised as antiapoptotic (O’Connor et al, 2002). In addition,
the TUNEL assay was used to detect the apoptotic status of the
GBMs and apoptotic status was correlated with the expression of
different Survivin forms. Our results, which extend previous results
of others (Chakravarti et al, 2002; Sasaki et al, 2002; Jiao et al, 2004)
that examined Survivin expression in human gliomas, are intended
to shed light on our understanding of the developmental genetic
mechanisms of primary and secondary GBMs.
MATERIALS AND METHODS
Patients and tissues specimens
In this study, 56 cases of GBM patients, whose clinical and
pathological information were available in detail, were selected
from the First Affiliated Hospital of Sun Yat-Sen University (SYSU,
Guang Zhou, China) from January 1990 to January 2000. The age of
patients at the time of surgery ranged from 9 to 67 years, and the
male/female ratio was 2.1:1. In all, 45 tumours were localised in
the hemispheres, six tumours were in the basal ganglia, and five
tumours were distributed in the brain stem. A total of 35 GBMs
were larger than 5cm in diameter, while 21 GBMs were no more
than 5cm in diameter.
Of the 56 patients studied, 30 were primary GBMs, 26 were
secondary GBMs. Diagnostic criteria for primary and secondary
GBM were according to a previous report (Watanabe et al, 1996).
Primary GBM was defined on the basis of clinical history of less
than 3 months and patient’s pathological diagnosis at the first
onset of GBM. The diagnosis of secondary GBM required at least
two biopsies and clinical as well as histological evidence of
progression from low-graded (II–III) glioma, but it was patholo-
gically diagnosed as GBM at the last operation. The clinical history
of secondary GBM was at minimum longer than 3 months. The
biopsy specimens, processed into paraffin blocks, of both primary
and secondary GBMs were obtained from the Department of
Pathology and Neurological Surgery, the First Affiliated Hospital of
SYSU. In addition, in these GBM series, 15 matched precursor
lesions (low-graded glioma) for secondary GBMs were also
available, in which 10 cases were grade II glioma and five were
anaplastic glioma (grade III).
Immunohistochemistry
Immunohistochemistry studies were performed using the SABC
method as previously described (Xie et al, 2003) with slight
modifications. For antigen retrieval, slides were microwave-treated
in a 50mM citrate buffer and boiled (pH 6.0) for 10min.
Nonspecific binding was blocked with 10% normal rabbit serum
for 20min. The tumour slides were incubated at 41C overnight in a
moist chamber with one of the two polyclonal anti-Survivin
antibodies (NB-500-201 K3, Novus Biologicals, Littleton, CO, USA,
1:300 dilution and SC-10811, Santa Cruz Biotechnology, Santa
Cruz, CA, USA, 1:400 dilution). Each antibody was known to
detect predominantly cytoplasmic (NB-500-201 K3) or the nuclear
(SC-10811) forms of Survivin (Altura et al, 2003). Negative
controls were established by replacing the primary antibody with
a normal rabbit Ig.
Evaluation of IHC results
Each IHC slide was assessed in 10 high-powered fields at  40
magnification, and Survivin staining was evaluated semiquantita-
tively. A staining score (to þþþþ) was obtained as the
proportion of immunopositive cells in each tumour. Expression of
Survivin was scored as ‘ ’ for negative expression, ‘þ’ for positive
staining in o25 cells, ‘þþ’ for positive staining in 25–50% cells,
‘þþþ’ for positive staining in 51–75% cells, and ‘þþþþ’ for
positive staining in 475% cells.
TUNEL assay
The fluorescent TUNEL staining was performed using a Death
Detection kit (Roche Diagnostic GmbH, Mannheim, Germany)
according to the manufacturer’s instructions. Briefly, the rehy-
drated section was microwave-treated in 10mM citrate buffer (pH
6.0) for 5min. After washing in PBS, the specimen was incubated
with a mixture of TdT solution (enzyme solution) and FITC-lablled
dUTP solution (fluorescence labled solution) in a humidified
chamber in the dark at 371C for 60min. After washing, the slide
was examined with a Zeiss Axiophot fluorescence microscope.
Negative controls were obtained by replacing the TdT solution
with distilled water. The presence of clear nuclear staining (TUNEL
positive, green colour) was indicative of apoptotic cells
(Figure 1G). At least 1000 tumour cell nuclei were examined. The
number of TUNEL-positive tumour cell nuclei was counted and
the apoptotic index (AI) was determined as the percentage of
apoptotic cells in the tumour. For evaluation of the TUNEL
staining, the mean value of AI of all samples under study was often
used as a cutoff value (Yamasaki et al, 1997). In this study, the
mean value of AI for all GBM samples was 0.76, thus, tumours were
classified into two groups according to their AI: low AI group
(AIo0.76) and high AI group (AIX0.76).
Statistical analysis
The differences in Survivin expression between primary and
secondary GBMs and the correlation of Survivin in GBM with
patient’s clinicopathological parameters and cell apoptosis were
assessed by w
2 test. Unpaired t-test was used to assess the statistical
significance of the differential recurrent times from precursor
lesion to secondary GBM, between groups with and without
Survivin expression. P-values of o0.05 were considered to be
significant.
RESULTS
Survivin expression in primary and secondary GBMs
Using two different Survivin antibodies, we were able to detect
predominantly cytoplasmic (NB-500–201 K3, Figure 1B–D) and
nuclear (SC-10811, Figure 1A, E, and F) forms of Survivin in GBMs
by IHC, although both antibodies had some overlapping reactivity.
The results of Survivin expression in GBMs are outlined in Tables
1 and 2. Of the 56 GBMs, 37 (66%) had cytoplasmic positive
staining of Survivin and 43 (77%) had nuclear positive staining of
Survivin. For the expression of Survivin in primary and secondary
GBMs, the frequency of cytoplasmic positive staining of Survivin
detected in primary GBMs was 83% (25 out of 30), which was
significantly greater than that in secondary GBMs (46%, 12 out of
26) (Po0.001). In contrast, nuclear expression of Survivin showed
no significant difference between primary and secondary GBMs
(P¼0.51), that is, the rate of nuclear positive staining of Survivin
in the primary GBMs was 73% (22 out of 30), and in the secondary
GBM group, 81% (21 out of 26).
Survivin expression in secondary GBMs and matched
precursor lesions
Owing to the suggestion that increased expression of Survivin in
human gliomas is positively correlated with an ascending
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spathological grade of tumour (Sasaki et al, 2002), we further
evaluated the expression pattern of Survivin between 15 pairs of
secondary GBMs and their pre-existing lower grade lesions.
Overall, the expression level (staining score) of nuclear and
cytoplasmic Survivin between the 15 matched secondary GBMs
and precursor lesions was concordant. That is, of the seven
secondary GBMs showing cytoplasmic positive of Survivin, six
paired precursor lesions also had positive cytoplasmic Survivin
staining and of the 11 secondary GBMs showing nuclear Survivin
positive staining, each of the paired precursor lesions also showed
positive nuclear Survivin (Table 3). The expression level (staining
score) of cytoplasmic Survivin in the secondary GBMs was higher
than that in paired pre-existing lower grade lesions in five of
the seven paired cases (Table 3, Figure 1C and D). A difference in
the expression level of nuclear Survivin between secondary GBMs
and paired pre-existing lower grade lesions was not observed
(Figure 1E and F).
Association of Survivin expression with clinicopathological
features
A potential association between GBM Survivin expression and
several known clinicopathological features, including patient’s age,
gender, tumour site, and tumour size, was further examined. No
significant association was observed between Survivin nuclear
expression and any of the patient’s clinicopathological parameters
(P40.05). In contrast, a significant association of Survivin
cytoplasmic expression with tumour size was observed (Po0.01).
Thus, 80% (28 out of 35) of the large-sized GBMs (tumour size
X5cm in diameter) were found to have positive expression of
Figure 1 Immunohistochemical staining of Survivin and fluorescent TUNEL staining in human gliomas (A–G). A primary glioblastoma showed a high level
(þþþþ) expression of nuclear Survivin (A). High staining score (þþþþ) of cytoplasmic Survivin was detected in another primary glioblastoma (B).
Moderate expression level (þþ) of cytoplasmic Survivin was detected in a pre-existing low-graded (grade II) glioma (C), which was obviously lower than
that in its paired secondary glioblastoma with a staining score of þþþþ(D). High-level (þþþþ) expression of nuclear Survivin was detected in a
secondary glioblastoma (E) and its matched pre-existing grade II glioma (F). Three apoptotic cells with clear nuclear staining (green color) were examined in
a primary glioblastoma (G).
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scytoplasmic Survivin, while only 43% (nine out of 21) of the small-
sized GBMs (o5cm in diameter) had positive expression of
cytoplasmic Survivin. Cytoplasmic Survivin expression did not
show a significant association with any other clinicopathological
parameters of the patient (P40.05). In secondary GBMs, the mean
progression times in months from precursor lesion onset to
secondary GBMs was significantly shorter in cytoplasmic Survivin-
positive cases (mean, 15.6 months) than that in cytoplasmic
Survivin-negative cases (mean, 23.8 moths, Po0.05), (Table 2).
Correlation of Survivin expression with cell apoptosis
In this study, the TUNEL assay was used to study the status of
apoptosis in all 56 GBMs. High AI (AIX0.76) was detected in 23
out of 56 (41%) of the tumours. Furthormore, a significant inverse
correlation between Survivin cytoplasmic expression and tumour
apoptosis was observed (P o0.001), that is, in the GBMs with
positive expression of cytoplasmic Survivin, 84% (31 out of 37)
were observed to have a low AI (AIo0.76), whereas in the GBMs
showing negativity of cytoplasmic Survivin (17 out of 19, 89%), a
high AI (AIX0.76) was found (see Table 1 and 2). No significant
correlation was observed between nuclear Survivin expression and
GBM AI.
DISCUSSION
GBM, the most malignant of human brain glial tumours, may
develop de novo (primary GBM) or via another pathogenic
pathway, that is, from a low-grade glioma (secondary GBM) and
the molecular alterations leading to the development of GBMs may
differ (Nakamura et al, 2000). A previous report has documented a
high frequent positive expression of Survivin in primary GBMs
(Das et al, 2002). However, the expression pattern of this protein
in secondary GBMs has not been described. In this study, the
differences of Survivin expression between primary and secondary
GBMs were examined by IHC using two different antibodies, one
which detects predominantly cytoplasmic Survivin and one
which detects predominantly nuclear forms of Survivin. Our
results provide evidence that the expression pattern of nuclear
Survivin was similar between primary and secondary GBMs, but,
in contrast, cytoplasmic Survivin positivity was significantly more
frequent in primary GBMs than that in secondary GBMs. It
appears, therefore, that cytoplasmic expression of Survivin may
provide additional insight into the developmental genetic mechan-
isms of GBM in different pathogenic pathways.
As discussed in detail in several intracellular localisation studies
of Survivin protein, at present, at least three different splice
variants of Survivin (ie, Survivin, Survivin delta Ex 3, and
Survivin-2B) have been identified and have different subcellular
localisations. Survivin and Survivin 2B isoforms localise predomi-
nantly to the cytoplasm, whereas the delta Ex 3 isoform is
preferentially localised in the nucleus (Mahotka et al, 2002).
Nuclear and cytoplasmic pools of Survivin have distinct roles.
Cytoplasmic Survivin has been characterised as antiapoptotic
(O’Connor et al, 2002), while nuclear Survivin has been proposed
to serve in the maintenance of the integrity of the mitotic spindle
(Uren et al, 2000). Germane to previous studies (Jiao et al, 2004),
we found an inverse correlation between the cytoplasmic expres-
sion of Survivin and cell apoptosis in our GBM cohorts, thus
suggesting an antiapoptotic function of the cytoplasmic form of
Survivin in GBMs. In addition, we observed a significant
association between Survivin cytoplasmic expression and GBM
tumour size. The positive of cytoplasmic Survivin expression was
found more frequently in large-sized GBMs (tumour size X5cmin
diameter) than that in small-sized GBMs, the latter in which
high-level cell apoptosis was more common. These results suggest
that the antiapoptotic activity of cytoplasmic Survivin may be
responsible, at least in part, for the growth and aggressive
behaviour of GBM tumour cells.
In secondary GBMs, we found that the positive expression level
of cytoplasmic Survivin was increased in most of secondary GBMs
when compared to their matched low-grade tumours from the
same patient, although the frequency of cytoplasmic Survivin
positivity was similar to that in paired pre-existing low-graded
lesions. In addition, the overall time in months of low-grade
precursor lesion progression to secondary GBM was substantially
less in cytoplasmic Survivin-positive cases than that of Survivin-
negative cases. These results suggest a potential tumorigenic role
of an upregulated expression of cytoplasmic Survivin along the
linear progression model of low-grade lesions to secondary GBM.
This also implies the possibility that the increased accumulation of
Survivin in cytoplasm opposes apoptotic death in the early less-
malignant glioma cells and thus may provide a selective advantage
and acceleration of progression from a lower grade glioma into a
higher grade more malignant phenotype. These observations, in
addition, may shed light on explaining why many gliomas, even at
their earliest stages, are so resistant to conventional apoptosis-
related chemotherapy and radiation. However, it also appears that
cytoplasmic Survivin accumulation is probably just one of several
mechanisms that glioma cells may use to evade apoptosis, as we
observed that more than 50% of secondary GBMs and their pre-
existing low-grade gliomas failed to express cytoplasmic Survivin.
An intriguing question that evolved in our studies is why is the
rate of cytoplasmic Survivin in secondary GBMs significantly lower
than that in primary GBMs? Although the pathogenic pathways
leading to the development of GBMs may differ, almost all GBMs
Table 1 Status of Survivin expression and apoptotic index in primary
GBMs
Case
no. Age/sex
Tumour
size (cm)
Cytoplasmic
Survivin
a
Nuclear
Survivin
a AI
b
1 11/M 5.7 +++   Low
2 15/M 3.1   ++ High
3 16/F 6.3 ++++ +++ Low
4 16/M 7.8 +++ +++ Low
5 19/M 4.3 ++ + Low
6 23/M 5.6 ++++ ++++ Low
7 27/F 7.3 ++++ +++ High
8 28/M 8.5 ++++ ++++ Low
9 30/F 6.4    High
10 33/M 5.1 +++ ++ High
11 35/M 3.5 ++++   Low
12 35/F 5.2   ++++ High
13 36/M 7.5 ++++ ++++ Low
14 37/M 10.2 +++ ++ High
15 38/M 5.8 +++   Low
16 39/M 7.6 ++++ +++ High
17 39/M 5.5 + +++ Low
18 40/M 5.9 +++   Low
19 40/M 2.7   + High
20 41/M 5.8 +   Low
21 41/M 3.4 +++ ++++ Low
22 42/F 5.8 ++++ ++++ Low
23 43/M 4.1 ++++ +++ Low
24 45/M 11.3 +++ +++ Low
25 46/M 4.4 ++++ ++ High
26 49/M 9.2 ++ ++++ Low
27 52/F 4.8   + High
28 53/M 5 ++ ++++ Low
29 61/M 6.8 ++++   Low
30 67/F 12 +++   Low
aExpression of Survivin detected by immunohistochemistry were scored as ‘ ’f o r
negative expression, ‘+’ for positivity in o25 cells, ‘++’ for positivity in 25–50% cells,
‘+++’ for positivity in 51–75% cells, and ‘++++’ for positivity in 475% cells.
bAI¼apoptotic index; AIX0.76 were scored as ‘high’, AIo0.76 were scored as ‘low’.
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stend to possess active proliferation, high invasiveness and
angiogenesis potential, resistance to conventional cytotoxic
treatments and most of these patients have survival times
less than 1 year (Davis et al, 1999). These similar neuropathologic
and behavioural features of both primary and secondary GBMs
imply that the criteria of clinicopathological classification for
GBM may not reflect their malignant potential. In addition, it is
also true that some of the primary GBMs may have rapidly
progressed from lower grade gliomas, which often are clinically
asymptomatic. Indeed, the positive expression levels of cyto-
plasmic Survivin in our primary GBMs were similar to that in our
secondary GBMs, although the frequency of positivity was
substantially higher in the former than in the later. These
observations, collectively, prompt us to hypothesise that the high
frequency of cytoplasmic Survivin in primary GBM may increase
the barriers to cell apoptosis, accelerate the oncogenic process of
primary GBM, in particular, facilitate the development of primary
GBM in a short period without an identifiable less-malignant
pre-existing lesion. Thus, if the above hypothesis has validity, it is
not so difficult to understand why Survivin accumulation in
cytoplasm is much more frequent in primary GBMs than that
in secondary GBMs.
For the nuclear form of Survivin, we found that its expression
pattern in secondary GBMs and paired low-graded precursor
lesions was almost concordant. This was consistent, in part, with
other observations, where no differential expression of nuclear
Survivin was observed between independent low-graded gliomas
and GBMs (Kleinschmidt-DeMasters et al, 2003). This suggests
the possibility that the positive expression of the nuclear form of
Survivin may be an early molecular event involved in the
development of secondary GBMs. Although the potential role of
nuclear Survivin and its mechanism of action in human cancers
are still unclear, Honda et al (2003) recently have observed that in
the nucleus, Survivin interacted with INCENP and aurora B kinase;
these enzymes have an important role in chromosomal segregation
during mitosis. Moreover, knockout or inhibition of Survivin has
been shown to result in multinucleated and polyploid cells, which
Table 2 Status of Survivin expression and apoptotic index in secondary GBMs
Preexisting lesion
Case no. Age/sex Tumour size (cm) Cytoplasmic Survivin
a Nuclear Survivin
a AI
b Grade Progressing time
c
1 9/M 6.3   +++ Low II 18
2 15/M 2.2    High II 36
3 16/M 5.8 ++++ +++ Low II 31
4 17/F 3.7 ++++ ++ High III 11
5 17/M 8.8   +++ High II 33
6 18/F 6.5 +++ ++++ Low III 4
7 23/F 4.9   ++++ High II 48
8 25/M 6.4    High II 23
9 27/M 3.1   + High III 18
10 29/M 10.2 +++   Low II 31
11 33/F 2.9   + High III 27
12 35/M 7.2 ++++ +++ Low II 22
13 38/F 6.3 ++ +++ Low II 21
14 39/M 4.3   ++ High III 32
15 41/M 9.3 ++++   Low III 7
16 43/F 5.8   ++ High II 24
17 43/M 3.0   ++ High II 11
18 44/F 5.1 ++++ +++ Low III 18
19 43/M 4.9    Low II 26
20 45/F 11.3   ++ High II 8
21 45/M 7.7 +++ +++ Low II 9
22 47/M 6.1 ++++ +++ Low III 6
23 49/F 2.3   + High II 24
24 55/F 9.7 ++++ ++++ Low III 16
25 60/M 3.8   ++++ High II 5
26 61/M 4.7 ++++ ++ Low III 11
aExpression of Survivin detected by immunohistochemistry were scored as ‘ ’ for negative expression, ‘+’ for positivity in o25 cells, ‘++’ for positivity in 25–50% cells, ‘+++’ for
positivity in 51–75% cells, and ‘++++’ for positivity in 475% cells.
bAI¼apoptotic index; AIX0.76 were scored as ‘high’, AIo0.76 were scored as ‘low’.
cThe times (months)
form the first onset of low-grade glioma progressing to secondary GBM.
Table 3 The expression of cytoplasmic and nuclear Survivin in 15 paired
secondary GBMs and pre-existing lesions
a
Cytoplasmic Survivin Nuclear Survivin
Case
no.
Secondary
GBM
Pre-existing
lesion
Secondary
GBM
Pre-existing
lesion
1    +++ +++
3 ++++ ++ +++ ++++
4 ++++ + ++ ++
5    +++ +++
7    ++++ ++++
8     
10 +++    
11   ++ +
15 ++++ +++   
17    ++ ++
19     
21 +++ +++ +++ +++
22 ++++ ++ +++ ++
25    ++++ ++++
26    ++ ++
aExpression of Survivin detected by immunohistochemistry were scored as ‘ ’ for
negative expression, ‘+’ for positivity in o25 cells, ‘++’ for positivity in 25–50% cells,
‘+++’ for positivity in 51–75% cells, and ‘++++’ for positivity in 475% cells.
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sis a characteristic of mitotic arrest (Speliotes et al, 2000). In our
GBM studies, the majority of GBMs showed an aneuploid DNA
content (Xie et al, 2005), and, furthermore, a close association
between nuclear Survivin positivity and tumour aneuploidy was
observed (data not shown). These results suggest that the nuclear
form of Survivin in GBMs may influence mitotic events and
subsequently facilitate chromosomal instability. It is known that
genetic instability can cause cytogenetic heterogeneity within a
number of tumour types, including gliomas (Harada et al, 1998).
Thus, it is quite possible that the widespread chromosomal
instability associated with nuclear expression of Survivin observed
in many GBMs can determine certain GBM histopathological
characteristics, such as the presence of tumour cell heterogeneity
and/or multiform tumour cells. However, the prognostic signifi-
cance of nuclear Survivin among human cancers does vary in
different tumour types. Recently, nuclear Survivin positivity has
been reported to be predictive of poor survival in patients with
oesophageal carcinoma and non-small-cell lung cancer (Grabowski
et al, 2003; Lu et al, 2004). In contrast, high nuclear Survivin
expression has been shown to be an independent indicator of a
favourable prognosis in osteosarcoma, breast cancer, and gastric
carcinomas (Okada et al, 2001; Kennedy et al, 2003; Trieb et al,
2003) and, moreover, it has been associated with a less-progressive
cytologic grade in pediatric ependymomas and choroid plexus
tumours of the brain (Altura et al, 2003). As regards to human
glioma, more recently, the index of nuclear expression of Survivin
has been observed to have a strong reverse association with the
overall survival time of glioma patients in different grades
(Uematsu et al, 2005). However, no prognostic impact of nuclear
expression of Survivin in GBM was observed (Preusser et al, 2005).
These observations suggest that the action of nuclear Survivin in
tumour cells may be tumour specific. Further studies are clearly
needed to elucidate the underlying function of nuclear Survivin in
GBMs as well as in other human cancers.
In summary, in the present study, we describe for the first time
the expression pattern of both nuclear and cytoplamic forms of
Survivin in primary and secondary GBMs. Our results indicate that
these different forms of Survivin (nuclear and cytoplasmic) have
different functions in influencing the malignant behaviour of
human glioma cells and these would have a profound effect on the
development and/or progression of primary and secondary GBMs.
Further studies designed to determine whether or not there is an
association between cytoplasmic and/or nuclear expression of
Survivin in GBM and GBM patients’ clinical outcomes are clearly
in order.
ACKNOWLEDGEMENTS
This study was supported by the Foundation of Developmental
Project of Science and Technology of Guang Dong, and Leung
Kwok Tze Foundation of Hong Kong, China.
REFERENCES
Adida C, Crotty P, McGrath J, Berrebi D, Diebold J, Altieri D (1998)
Developmentally regulated expression of the novel cancer anti-apoptosis
gene survivin in human and mouse differentiation. Am J Pathol 152:
43–49
Altura RA, Olshefski RS, Jiang Y, Boue DR (2003) Nuclear expression of
survivin in paediatric ependymomas and choroid plexus tumours
correlates with morphologic tumour grade. Br J Cancer 89: 1743–1749
Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene,
survivin, expressed in cancer and lymphoma. Nat Med 3: 917–921
Chakravarti A, Noll E, Black PM, Finkelstein DF, Finkelstein DM, Dyson NJ,
Loeffler JS (2002) Quantitatively determined survivin expression levels
are of prognostic value in human gliomas. J Clin Oncol 20: 1063–1068
Das A, Tan WL, Teo J, Smith DR (2002) Expression of survivin in primary
glioblastomas. J Cancer Res Clin Oncol 128: 302–306
Davis FG, McCarthy BJ, Freels S, Al E (1999) The conditional probability of
survival of patients with primary malignant brain tumors: surveillance,
epidemiology, and end results (SEER) data. Cancer 85: 485–491
Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, Heine B, Stein H, Hopfner M,
Germer CT, Scherubl H (2003) Prognostic value of nuclear survivin
expression in oesophageal squamous cell carcinoma. Br J Cancer 88:
115–119
Harada K, Nishizaki T, Ozaki S, Kubota H, Ito H, Sasaki K (1998)
Intratumoral cytogenetic heterogeneity detected by comparative genomic
hybridization and laser scanning cytometry in human gliomas. Cancer
Res 58: 4694–4700
Honda R, Korner R, Nigg EA (2003) Exploring the functional interactions
between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 14:
3325–3341
Jiao B, Yao Z, Geng S, Zuo S (2004) Expression of survivin, a novel
apoptosis inhibitor and cell regulatory protein, in human gliomas. Chin
Med J 117: 612–614
Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A,
Nishiwaki T, Moriyama S, Kudo J, Fujii Y (2001) Expression of survivin
in esophageal cancer: correlation with the prognosis and response to
chemotherapy. Int J Cancer 95: 92–95
Kawasaki H, Altieri D, Lu C, Toyoda M, Tenjo T, Tanigawa N (1998)
Inhibition of apoptosis by survivin predicts shorter survival rates in
colorectal cancer. Cancer Res 58: 5071–5074
Kennedy SM, O’Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill
AD, O’Higgins NJ, Parkinson M, Linehan R, Clynes M (2003) Prognostic
importance of survivin in breast cancer. Br J Cancer 88: 1077–1083
Kleinschmidt-DeMasters BK, Heinz D, McCarthy PJ, Bobak JB, Lillehei KO,
Shroyer ALW, Shroyer KR (2003) Survivin in glioblastomas, protein and
messenger RNA expression and comparison with telomerase level. Arch
Pathol Lab Med 127: 826–833
Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, Hallahan
DE (2004) Nuclear survivin as a biomarker for non-small-cell lung
cancer. Br J Cancer 91: 537–540
Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE,
Gerharz CD (2002) Differential subcellular localization of functionally
divergent survivin splice variants. Cell Death Differ 9: 1334–1342
Monzo M, Rosell R, Felip E, Astudillo J, Sanchez J, Maestre J, Martin C,
Font A, Barnadas A, Abad A (1999) A novel antiapoptosis gene: re-
expression of survivin messenger RNA as a prognosis marker in non-
small-cell lung cancers. J Clin Oncol 17: 2100–2104
Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H
(2000) Loss of heterozygosity on chromosome 19 in secondary
glioblastomas. J Neuropathol Exp Neurol 59: 539–543
O’Connor DS, Wall NR, Porter AC, Altieri DC (2002) A p34(cdc2) survival
checkpoint in cancer. Cancer Cell 2: 43–54
Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, Takano Y
(2001) Survivin expression in tumor cell nuclei is predictive of a
favorable prognosis in gastric cancer patients. Cancer Lett 163: 109–116
Preusser M, Gelpi E, Matej R, Marosi C, Dieckmann K, Rossler K, Budka H,
Hainfellner JA (2005) No prognostic impact of survivin expression in
glioblastoma. Acta Neuropathol 109: 534–538
Sasaki T, Lopes MB, Hankins GR, Helm GA (2002) Expression of survivin,
an inhibitor of apoptosis protein, in tumors of the nervous system. Acta
Neuropathol 104: 105–109
Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK,
Oh BH (2001) An anti-apoptotic protein human survivin is a direct
inhibitor of caspase-3 and -7. Biochemistry 40: 1117–1123
Speliotes EK, Uren A, Vaux D, Horvitz HR (2000) Survivin and the inner
centromere protein INCENP show similar cell-cycle localization and gene
knockout phenotype. Curr Biol 10: 1319–1328
Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR (2003) Survivin
expression in human osteosarcoma is a marker for survival. Eur J Surg
Oncol 29: 379–382
Uematsu M, Ohsawa I, Aokage T, Nishimaki K, Matsumoto K, Takahashi H,
Asoh S, Teramoto A, Ohta S (2005) Prognostic significance of the
immunohistochemical index of survivin in glioma: a comparative study
with the MIB-1 index. J Neurooncol 72: 231–238
Survivin in glioblastoma
D Xie et al
113
British Journal of Cancer (2006) 94(1), 108–114 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sUren AG, Wong L, Pakusch M, Fowler KJ, Burrows FJ, Vaux DL, Choo KH
(2000) Survivin and the inner centromere protein INCENP show
similar cell-cycle localization and gene knockout phenotype. Curr Biol
10: 1319–1328
Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H
(1996) Overexpression of the EGF receptor and p53 mutations are
mutually exclusive in the evolution of primary and secondary
glioblastomas. Brain Pathol 6: 217–224
Xie D, Sham JS, Zeng WF, Lin HL, Che LH, Wu HX, Wen JM, Fang Y,
Hu L, Guan XY (2003) Heterogeneous expression and association of
beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and
progression detected by tissue microarray. Int J Cancer 107: 896–902
Xie D, Zeng YX, Wang HJ, Tai LS, Wen JM, Tao Y, Ma NF, Hu L, Sham JS,
Guan XY (2005) Amplification and overexpression of epidermal growth
factor receptor gene in glioblastomas of Chinese patients correlates with
patient/s age but not with tumor’s clinicopathological pathway. Acta
Neuropathol [Epub ahead of print]
Yamasaki F, Tokunaga O, Sugimori H (1997) Apoptotic index in ovarian
carcinoma: correlation with clinicopathologic factors and prognosis.
Gynecol Oncol 66: 439–448
Survivin in glioblastoma
D Xie et al
114
British Journal of Cancer (2006) 94(1), 108–114 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s